Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPro1595 in Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976Phase 2Completed
- Sponsor
- INmune Bio Inc.
- Start
- Feb 2022
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 2 trial of pegipanermin in Alzheimer's disease (AD), sponsored by INmune Bio Inc.. Started Feb 2022; status: completed.
02
Drugs
pegipanermin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05318976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318976.